<DOC>
	<DOCNO>NCT01280747</DOCNO>
	<brief_summary>The investigator hypothesize fibromyalgia ( FM ) painful diabetic peripheral neuropathy ( pDPN ) patient access restriction pregabalin lead high healthcare resource use cost compare patient without restriction pregabalin naturalistic setting . The randomization occur physician level patient level .</brief_summary>
	<brief_title>Examination Pregabalin Access Treatment Indicated Pain Disorders : ExPAND Study</brief_title>
	<detailed_description>This trial terminate prematurely April 2 , 2012 , due inability recruit plan number subject . The decision terminate trial base safety efficacy concern .</detailed_description>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Somatoform Disorders</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>A physicianconfirmed diagnosis either pDPN FM , . Initiation medication pDPN FM clinically indicate , either monotherapy combination treatment , determine treat physician , agree patient . No prior pregabalin use pregabalin PA request . Age &lt; 18 year time study enrollment . Females partner male currently pregnant/lactating intend become pregnant next 6 month Physicianconfirmed diagnosis pDPN FM .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Prior authorization</keyword>
	<keyword>Fibromyalgia</keyword>
	<keyword>Painful Diabetic Peripheral Neuropathy</keyword>
	<keyword>Policy</keyword>
	<keyword>Real World Data</keyword>
</DOC>